Tamara Pilishvili
Overview
Explore the profile of Tamara Pilishvili including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
4189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosenthal M, Stoecker C, Leidner A, Cho B, Pilishvili T, Kobayashi M
Vaccine
. 2024 Dec;
44:126567.
PMID: 39645434
Background: In June 2021, the Advisory Committee on Immunization Practices (ACIP) recommended use of either 20-valent pneumococcal conjugate vaccine (PCV20) alone or 15-valent pneumococcal conjugate vaccine (PCV15) in series with...
2.
Andrejko K, Gierke R, Rowlands J, Rosen J, Thomas A, Landis Z, et al.
Vaccine
. 2024 May;
42(16):3555-3563.
PMID: 38704263
Background: A U.S. case-control study (2010-2014) demonstrated vaccine effectiveness (VE) for ≥ 1 dose of the thirteen-valent pneumococcal conjugate vaccine (PCV13) against vaccine-type (VT) invasive pneumococcal disease (IPD) at 86 ...
3.
Rivers P, Porter C, LeClair L, Jeddy Z, Fowlkes A, Lamberte J, et al.
Vaccine
. 2024 Feb;
42(7):1512-1520.
PMID: 38307743
Objectives: Pediatric COVID-19 vaccine hesitancy and uptake is not well understood. Among parents of a prospective cohort of children aged 6 months-17 years, we assessed COVID-19 vaccine knowledge, attitudes, and...
4.
Safari D, Daningrat W, Milucky J, Khoeri M, Paramaiswari W, Tafroji W, et al.
PLoS One
. 2024 Jan;
19(1):e0297041.
PMID: 38206916
Pneumococcal conjugate vaccines (PCVs) prevent nasopharyngeal colonization with vaccine serotypes of Streptococcus pneumoniae, leading to reduced transmission of pneumococci and stronger population-level impact of PCVs. In 2017 we conducted a...
5.
Plumb I, Mohr N, Hagen M, Wiegand R, Dumyati G, Harland K, et al.
Open Forum Infect Dis
. 2023 Oct;
10(10):ofad457.
PMID: 37799130
Background: Protection against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019 [COVID-19]) can limit transmission and the risk of post-COVID conditions, and is particularly important among...
6.
Sternberg M, Johnson A, King J, Ali A, Linde L, Awofeso A, et al.
PLoS One
. 2023 Sep;
18(9):e0291678.
PMID: 37729332
Background: SARS-CoV-2 Omicron variants have the potential to impact vaccine effectiveness and duration of vaccine-derived immunity. We analyzed U.S. multi-jurisdictional COVID-19 vaccine breakthrough surveillance data to examine potential waning of...
7.
Kobayashi M, Pilishvili T, Farrar J, Leidner A, Gierke R, Prasad N, et al.
MMWR Recomm Rep
. 2023 Sep;
72(3):1-39.
PMID: 37669242
This Report Compiles And Summarizes All Published Recommendations From Cdc’s Advisory Committee On Immunization Practices (acip) For Use Of Pneumococcal Vaccines In Adults Aged ≥19 Years In The United States....
8.
Farrar J, Childs L, Ouattara M, Akhter F, Britton A, Pilishvili T, et al.
Pathogens
. 2023 May;
12(5).
PMID: 37242402
New pneumococcal conjugate vaccines (PCVs), 15- and 20-valent (PCV15 and PCV20), have been licensed for use among U.S. adults based on safety and immunogenicity data compared with the previously recommended...
9.
Ciesla A, Wiegand R, Smith Z, Britton A, Fleming-Dutra K, Miller J, et al.
Open Forum Infect Dis
. 2023 May;
10(5):ofad187.
PMID: 37213428
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.2/BA.2.12.1 and BA.4/BA.5 subvariants have mutations associated with increased capacity to evade immunity when compared with prior variants. We evaluated mRNA...
10.
Kobayashi M, Pilishvili T, Lessa F
JAMA Intern Med
. 2023 Apr;
183(6):624.
PMID: 37036715
No abstract available.